Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial
Open Access
- 10 March 2009
- journal article
- research article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 8 (4), 334-344
- https://doi.org/10.1016/s1474-4422(09)70049-3
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New GuineaPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2008
- A systematic review of prion therapeutics in experimental modelsBrain, 2006
- Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazineSurgical Neurology, 2005
- A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapieBritish Journal of Pharmacology, 2005
- Rational targeting for prion therapeuticsNature Reviews Neuroscience, 2005
- Treatment of Transmissible Spongiform Encephalopathy by Intraventricular Drug Infusion in Animal ModelsJournal of Virology, 2004
- Quinacrine‐induced cytolytic hepatitis in sporadic Creutzfeldt–Jakob diseaseAnnals of Neurology, 2003
- REPEATED SUPPRESSION OF CREUTZFELDT-JAKOB DISEASE WITH VIDARABINEThe Lancet, 1982
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 1975
- ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESSThe Lancet, 1974